Health Care & Life Sciences » Pharmaceuticals | Cocrystal Pharma Inc.

Cocrystal Pharma Inc.

Cocrystal Pharma Inc.
Stock Exchange OTCBB
EPS
$1.49
Market Cap
$70.51 M
Shares Outstanding
31.62 M
Public Float
9.68 M

Profile

Address
19805 North Creek Parkway
Bothell Washington 98011
United States
Employees -
Website http://www.cocrystalpharma.com
Updated 07/08/2019
Cocrystal Pharma, Inc. is a clinical stage biotechnology company, which engages in discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of Hepatitis C. Phase 1b studies in Hepatitis C infected patients showed the largest reduction in viral load of any non-neoside inhibitor tested to date.

Financials

View All

Gary L. Wilcox
Vice Chairman & Chief Executive Officer
Raymond F. Schinazi
Chairman